Four Democratic senators have published a report rebutting Novartis’ account of the details behind its consulting deal with Michael Cohen, President Donald Trump’s former attorney. More: Senators challenge Novartis' account of Cohen deal, calling it 'longer and more detailed' than
read moreWhile support from drug companies can be helpful for patients, sometimes support from others struggling with a disease can be even more helpful. So Bayer is offering both. More: Adempas maker Bayer connects hypertension patients with new mentoring group Source:
read moreAs Beijing and Washington exchange harsh words over President Trump’s renewed threat of additional tariffs, China is preparing to open up its pharma market further for a neighbor that it hasn’t historically had a good relationship with. More: As U.S.
read moreA ruling from the U.S. Patent and Trademark Office pushes Novartis’ exclusivity on Gilenya from 2019 to 2027. That will give Celgene more time to secure FDA approval for its Gilenya rival and persuade physicians that it’s a safer alternative
read moreSouth Korean investment firm SK Holdings got a start in contract manufacturing last year by snatching up a discarded Big Pharma plant in Europe. Now it has made a move on the U.S. with a deal to buy AMPAC, a
read more“The ‘NHS Challenge’ is designed specifically for agencies that have strong experience in dealing with UK specific challenges,” says the executive steering group’s Eric Hansen. More: Put your agency in the spotlight, ENTER NOW Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals